U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Drug Safety-related Labeling Changes

Drug Safety-related Labeling Changes (SrLC)

Get Email Alerts | Guide

ANDROGEL (NDA-021015)

(TESTOSTERONE)

Safety-related Labeling Changes Approved by FDA Center for Drug Evaluation and Research (CDER)

Download Data

Expand all

07/11/2025 (SUPPL-47)

Approved Drug Label (PDF)

5 Warnings and Precautions

5.13 Lipid Changes

Additions and/or revisions underlined:

Changes in serum lipid profile may require dose adjustment or discontinuation of testosterone therapy, such as AndroGel 1%. Monitor the lipid profile periodically, particularly after starting testosterone therapy.

5.3 Venous Thromboembolism

Additions and/or revisions underlined:

…

In the Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study, a randomized, double-blind, placebo-controlled, cardiovascular (CV) outcomes study, compared to placebo, AndroGel 1.62% was associated with a numerically higher incidence of VTE (1.7% vs 1.2%) which included DVT (0.6% vs 0.5%) and PE events (0.9% vs 0.5%) [see Adverse Reactions (6.1)].

…

5.5 Blood Pressure Increases

Subsection title revised. Additions and/or revisions underlined:

AndroGel 1% can increase blood pressure. In an ambulatory blood pressure monitoring (ABPM) study, Androgel 1.62% increased the mean systolic/diastolic blood pressure by 1.9/1.3 mm Hg from baseline after 16 weeks of treatment. In patients with hypertension on antihypertensive therapy, AndroGel 1.62% increased the mean systolic/diastolic BP by 3.0/2.2 mm Hg from baseline. Blood pressure increases can increase cardiovascular (CV) risk over time.

The CV risk associated with Androgel 1.62% was evaluated in TRAVERSE, a randomized, double-blind, placebo-controlled, CV outcomes study in men with a history of CV disease or multiple CV risk factors. In TRAVERSE, mean systolic blood pressure in the group treated with Androgel 1.62% was increased by 1.0 mm Hg from baseline to 36 months, whereas a mean decrease from baseline of 0.5 mm Hg was observed in the placebo group at this timepoint, for a mean between-group difference of 1.5 mm Hg. However, the incidences of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction [MI] and non-fatal stroke, were similar between treatment groups (7% for Androgel 1.62% vs 7.3% for placebo) [See Adverse Reactions (6.1)].

Monitor blood pressure periodically in men using Androgel 1.62%, especially men with hypertension. Androgel 1.62% is not recommended for use in patients with uncontrolled hypertension.

5.7 Not for Use in Women

Subsection title revised; revision underlined:

Due to lack of controlled evaluations in women and potential virilizing effects, AndroGel 1% is not indicated for use in women [see Contraindications (4) and Use in Specific Populations (8.1, 8.2)].

6 Adverse Reactions

6.1 Clinical Trials Experience

Additions and/or revisions underlined:

…

Blood Pressure Increases

In a 4-month clinical study, 24-hour ambulatory blood pressure monitoring (ABPM) was conducted on 246 patients. ABPM was conducted at baseline and at Week 16 of AndroGel 1.62% therapy. A total of 169 patients had acceptable ABPM recordings at both baseline and Week 16 and also were at least 85% compliant with study drug. In that group, the mean change in 24-hour systolic blood pressure (BP) and diastolic BP from baseline to end-of-treatment at Week 16 (n=169) was 1.9 mm Hg (95% CI 0.6, 3.1) and 1.3 mm Hg (95% CI 0.5, 2.1), respectively. In patients with a history of hypertension who were being treated with antihypertensive therapy, the mean ABPM systolic and diastolic BP increased by 3.0 mm Hg [95% CI 0.8, 5.2] and 2.2 mm Hg [95% CI 0.8, 3.5], respectively [n=72]). In patients with no history of hypertension at baseline, the mean systolic and diastolic blood pressure increased by

1.2 mm Hg [95% CI -0.2, 2.7] and 0.9 mm Hg [95% CI -0.1, 1.8], respectively [n=91]).

Four patients (2.8%) on AndroGel 1.62%, all of whom were receiving antihypertensive medications at baseline, either started new antihypertensive medications (n=2) or had their antihypertensive regimen adjusted during the ABPM study.

Of the 246 patients who used Androgel during the study, 10 patients (4.1%) were reported to have either an adverse reaction of hypertension (5 patients, 2.0%) or increased blood pressure (5 patients, 2.0%).

Cardiovascular Outcomes

TRAVERSE was a randomized, double-blind, cardiovascular outcomes study to assess the CV safety of Androgel 1.62% compared to placebo in 5198 hypogonadal men aged 45 to 80 years with a history of CV disease or with multiple CV risk factors. The primary outcome was the incidence of the composite endpoint of major adverse cardiovascular events (MACE), consisting of CV death, non-fatal myocardial infarction (MI), and non-fatal stroke.

The mean duration of therapy was approximately 22 months. The mean duration of follow-up was 33 months. Approximately 61% of all patients discontinued AndroGel 1.62% or placebo therapy. The mean (±SD) daily dose of testosterone was 65±22 mg.

The mean patient age (±SD) was 63.3 (7.9) years, with 2452 patients aged 65 years or more (47%); 2847 (about 55%) patients had pre-existing cardiovascular disease, whereas 2357 patients (about 45%) had an elevated cardiovascular risk at baseline, and mean BMI was 35kg/m2.

Approximately 80% of patients were White, 17% were Black, and 3% were of other races or ethnic groups. Approximately 69%, 84%, and 93% had diabetes mellitus, hyperlipidemia, and hypertension, respectively.

The mean serum testosterone concentration at baseline in patients receiving AndroGel 1.62% was 220.4 ng/dL (n= 2596). The mean serum testosterone concentrations at 12 months, 24 months, 36 months, and 48 months in patients receiving AndroGel 1.62% were 440.5 ng/dL (n=1683), 420.9 ng/dl (n=1125), 428.7 ng/dL (n=731), and 365.2 ng/dL (n=220), respectively.

For patients treated with AndroGel 1.62%, the incidence of MACE was 7.0% (n=182 events) and for those receiving placebo, the incidence of MACE was 7.3% (n=190 events). The study demonstrated non-inferiority of AndroGel 1.62% versus placebo because the upper bound of 95% CI was less than the pre-specified risk margin, of 1.5 for MACE (Hazard Ratio 0.96 [95% CI: 0.78, 1.17]).

Additional Adverse Reactions Reported in TRAVERSE

Additional adverse reactions reported in TRAVERSE at an incidence rate >2% in either treatment group and greater in AndroGel 1.62% versus placebo included: nonfatal arrythmias warranting intervention (5.2% vs 3.3%), atrial fibrillation (3.5% vs 2.4%), acute kidney injury (2.3% vs 1.5%) and bone fracture (3.5% vs 2.5%). For the adverse reaction of bone fracture, each event was adjudicated by clinical review.

17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)

PATIENT COUNSELING INFORMATION

17.3 Potential for Venous Thromboembolism

New subsection added:

Inform patients that AndroGel 1% can cause venous thromboembolism. Advise patients of the signs and symptoms of venous thromboembolism, which may include the following: lower limb pain, edema, or erythema; and dyspnea or chest pain. Advise patients to promptly report the signs and symptoms of venous thromboembolism, discontinue use of AndroGel 1%, and seek urgent medical care.

17.4 Potential for Increase in Blood Pressure

New Subsection added:

Inform patients that AndroGel 1.62% can increase BP which can increase cardiovascular risk over time. Instruct patients about the importance of monitoring BP periodically while on Androgel 1%. If BP increases while on AndroGel 1%, antihypertensive medications may need to be started, added, or adjusted to control BP, or AndroGel 1% may need to be discontinued.

MEDICATION GUIDE

Additions and/or revisions underlined:

…

Before using ANDROGEL 1%, tell your healthcare provider about all of your medical conditions, including if you:

…

  • Have high blood pressure or are being treated for high blood pressure.

    …

    What are the possible side effects of ANDROGEL 1%?

    ANDROGEL 1% can cause serious side effects including:

    …

  • Increase in blood pressure. AndroGel 1% can increase your blood pressure. Increases in blood pressure can increase the risk of heart attack or stroke over time. If your blood pressure increases while on AndroGel 1%, blood pressure medicines may need to be started. If you are taking blood pressure medicines, new blood pressure medicines may need to be added or your current blood pressure medicines may need to be adjusted to control your blood pressure. If your blood pressure cannot be controlled, AndroGel 1% may need to be stopped. Your healthcare provider will monitor your blood pressure while you are being treated with AndroGel 1%.

    …

           

05/10/2019 (SUPPL-45)

Approved Drug Label (PDF)

4 Contraindications

(Additions and/or revisions are underlined)

  • AndroGel 1% is contraindicated in women who are pregnant. AndroGel 1% can cause virilization of the female fetus when administered to a pregnant woman. Pregnant women need to be aware of the potential for transfer of testosterone from men treated with AndroGel 1%. If a pregnant woman is exposed to AndroGel 1%, she should be apprised of the potential hazard to the fetus.

02/25/2019 (SUPPL-44)

Approved Drug Label (PDF)

8 Use in Specific Populations

8.1 Pregnancy

8.2 Lactation

8.3 Females and Males of Reproductive Potential

PLLR conversion; extensive changes. Please refer to label for complete information.

10/25/2016 (SUPPL-43)

Approved Drug Label (PDF)

5 Warnings and Precautions

5.6 Abuse of Testosterone and Monitoring of Serum Testosterone Concentrations ( subsection added)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. Anabolic androgenic steroid abuse can lead to serious cardiovascular and psychiatric adverse reactions

If testosterone abuse is suspected, check serum testosterone concentrations to ensure they are within therapeutic range. However, testosterone levels may be in the normal or subnormal range in men abusing synthetic testosterone derivatives. Counsel patients concerning the serious adverse reactions associated with abuse of testosterone and anabolic androgenic steroids. Conversely, consider the possibility of testosterone and anabolic androgenic steroid abuse in suspected patients who present with serious cardiovascular or psychiatric adverse events.